Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer

Abstract excerpt

Second-line treatment with immune checkpoint inhibition in patients with metastatic urothelial cancer (mUC) has a low success rate (~ 20%). Circulating tumour-derived DNA (ctDNA) levels may guide patient stratification, provided that an affordable and robust assay is available. Here, we investigate whether the modified fast aneuploidy screening test-sequencing system (mFast-SeqS) may provide such an assay. To...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bladder and Urothelial Cancer Treatments
• Share to Cancer Genomics and Diagnostics
• Share to Infectious Disease Case Reports and Treatments